Kisqali
Novartis Raises Sales Targets for Key Cancer Drugs, Tweaks Yearly Growth Guidance
Novartis; Kisqali; Scemblix; Pluvicto; sales guidance; peak sales forecast; cancer drugs; breast cancer; leukemia; pharmaceutical industry
Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer
Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
Novartis’ Kisqali Secures Broad FDA Approval for Adjuvant Treatment of Early Breast Cancer
Kisqali, Novartis, FDA Approval, Early Breast Cancer, Adjuvant Treatment, HR+/HER2- Breast Cancer, CDK4/6 Inhibitors